^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ADCT-701

    i
    Other names: ADCT-701, ADCT 701
    Company:
    ADC Therapeutics
    Drug class:
    DNA replication inhibitor, DLK1-targeted antibody-drug conjugate
    Related drugs:
    1m
    Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas (clinicaltrials.gov)
    P1, N=70, Recruiting, National Cancer Institute (NCI) | Not yet recruiting --> Recruiting | Trial completion date: Oct 2028 --> Oct 2029 | Trial primary completion date: Oct 2026 --> Oct 2027
    Enrollment open • Trial completion date • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    ADCT-701
    8ms
    Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas (clinicaltrials.gov)
    P1, N=70, Not yet recruiting, National Cancer Institute (NCI)
    New P1 trial
    |
    CD4 (CD4 Molecule)
    |
    ADCT-701